Rapid and fatal acute heart failure induced by pazopanib

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are effective cancer treatments.
• Pazopanib is a TKI used for various cancers.
• Cardiotoxicity is a potential side effect of TKIs.

Observation:

• A 51-year-old woman with thoracic sarcoma developed fatal heart failure while on pazopanib.
• The patient had prior anthracycline exposure but no other cardiovascular risk factors.
• Cardiac function was normal before pazopanib initiation.

Findings:

• Despite initial tumor response, the patient experienced fatigue and required pazopanib interruption.
• Upon reintroduction at a reduced dose, she developed acute, severe heart failure.
• Elevated Brain Natriuretic Peptide and echocardiographic findings confirmed heart failure.

Implications:

• This case underscores the potential for pazopanib-induced cardiotoxicity, even in patients without traditional risk factors.
• Close cardiac monitoring is crucial for patients undergoing TKI therapy.
• Further research into TKI cardiotoxicity mechanisms and prevention strategies is warranted.